tamsulosin

The drug is indicated for the treatment of men with symptoms of benign prostatic hyperplasia. It helps with frequent or urgent urges to urinate, as well as difficulties with the bladder emptying process itself.

Form: tablets, modified release

ATC: G04CA53

Manufacturer: Adamed Pharma S.A. (manufacturing, primary and secondary packaging, batch control and batch release)

The drug is used to treat functional lower urinary tract disorders occurring in benign prostatic hyperplasia.

Form: capsules, modified release, hard

ATC: G04CA02

Manufacturer: JSC "Kyiv Vitamin Plant"

The drug is used to treat lower urinary tract symptoms in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: tablets, film-coated, modified release

ATC: G04CA02

Manufacturer: Apotex Inc.

The drug is used to treat moderate to severe symptoms of benign prostatic hyperplasia. It helps reduce the risk of acute urinary retention and the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: Catalent Germany Schoorl GmbH

The drug is prescribed for the treatment of moderate to severe symptoms of benign prostatic hyperplasia, as well as to reduce the risk of acute urinary retention and the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: STADA Arzneimittel AG (batch release)

The drug is intended for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. It helps reduce the risk of acute urinary retention and lowers the likelihood of the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: Laboratorios Leon Farma, S.A. (manufacturing of intermediate product (soft capsules Dutasteride 0.5 mg) and finished medicinal product, primary and secondary packaging; quality control and batch release)

The drug is used to treat moderate to severe symptoms of benign prostatic hyperplasia. It helps facilitate urination, reduces the risk of acute urinary retention, and decreases the likelihood of requiring surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: GALENICUM HEALTH, S.L. (quality control testing (physical/chemical), batch release; manufacturer of intermediate product - Dutasteride, soft capsules, 0.5 mg: quality control testing (physical/chemical), batch release; manufacturer of intermediate product - Tamsulosin hydrochloride, pellets, 0.4 mg: quality control testing (physical/chemical), batch release)

The drug is intended for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. It helps reduce the risk of acute urinary retention and the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: SAG MANUFACTURING, S.L.U. (manufacturing, primary and secondary packaging, quality control and batch release)

The drug is prescribed for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. It helps reduce the risk of acute urinary retention and the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: Laboratorios Leon Farma S.A. (manufacturing of intermediate product - soft gelatin capsules and manufacturing of medicinal products, primary and secondary packaging, quality control, responsible for batch release)

The drug is used to treat lower urinary tract functional disorders in benign prostatic hyperplasia.

Form: capsules, hard with modified release

ATC: G04CA02

Manufacturer: Famar A.V.E. Antoussa Plant (manufacturing "in bulk", packaging, batch control)

The drug is used to treat functional disorders of the lower urinary tract that occur in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, hard with modified release

ATC: G04CA02

Manufacturer: Zentiva S.A.

The drug is used to treat functional lower urinary tract disorders associated with benign prostatic hyperplasia.

Form: capsules, extended-release

ATC: G04CA02

Manufacturer: Aurobindo Pharma Limited - Unit VII

The drug is used to treat functional urinary tract disorders in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, prolonged-release

ATC: G04CA02

Manufacturer: PJSC "Tekhnolog"

The drug is used to treat lower urinary tract symptoms arising from benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, modified release, hard

ATC: G04CA02

Manufacturer: ALKALOID AD Skopje (batch release)

The drug is intended for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. It helps reduce the risk of acute urinary retention and decreases the likelihood of the need for surgical intervention.

Form: capsules, hard

ATC: G04CA52

Manufacturer: Laboratorios Leon Farma S.A. (production of intermediate products (dutasteride soft gelatin capsules), and finished medicinal product; primary and secondary packaging, quality control (chemical/physical))

The drug is used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, modified release, hard

ATC: G04CA02

Manufacturer: Delpharm Meppel B.V.

The drug is used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (enlargement of the prostate).

Form: tablets, film-coated, prolonged release

ATC: G04CA02

Manufacturer: Delpharm Meppel B.V.

The drug is intended for the treatment of men with symptoms of benign prostatic hyperplasia. It helps with frequent or urgent urges to urinate and also improves the bladder emptying process.

Form: tablets, modified release

ATC: G04CA53

Manufacturer: Synthon Hispania, S.L. (production of finished dosage form, primary and secondary packaging, batch control, batch release)

The drug is used to treat functional urinary tract disorders occurring in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, modified release, hard

ATC: G04CA02

Manufacturer: Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)

The drug is used to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (enlargement of the prostate gland).

Form: tablets, extended-release

ATC: G04CA02

Manufacturer: Synthon Hispania, S.L. (manufacturing, primary, secondary packaging, quality control, batch release)

The drug is used to treat functional urinary tract disorders occurring in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules

ATC: G04CA02

Manufacturer: San Pharmaceutical Industries Limited

The drug is used to treat functional urinary tract disorders arising from benign prostatic hyperplasia (enlargement of the prostate gland).

Form: tablets, extended-release

ATC: G04CA02

Manufacturer: Synthon Hispania, S.L. (full-cycle manufacturing)

The drug is used to treat functional urinary tract disorders caused by benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, modified release

ATC: G04CA02

Manufacturer: PJSC "Scientific-Production Center "Borshchahivskiy Chemical-Pharmaceutical Plant" (packaging from 'in bulk' form by manufacturers Syntor Hispania S.L., Spain; Famar A.V.E. Antoussa Plant, Greece; Rottendorf Pharma GmbH, Germany)

The drug is used to treat functional lower urinary tract disorders occurring in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, modified release, hard

ATC: G04CA02

Manufacturer: STADA Arzneimittel AG (batch release)

The drug is intended for the treatment of functional urinary tract disorders occurring in benign prostatic hyperplasia.

Form: tablets, extended-release

ATC: G04CA02

Manufacturer: KRKA, d.d., Novo Mesto (primary and secondary packaging, batch control (chemical/physical and microbiological testing) and batch release) / KRKA, d.d., Novo Mesto (batch control (chemical/physical testing))

The drug is used to treat functional urinary tract disorders occurring in benign prostatic hyperplasia (enlargement of the prostate gland).

Form: capsules, extended-release, hard

ATC: G04CA02

Manufacturer: Macleods Pharmaceuticals Limited

The drug is prescribed to men to treat bladder storage symptoms (frequent or urgent urges to urinate) and bladder emptying symptoms (difficulty with voiding) associated with benign prostatic hyperplasia, if other treatment methods have not helped.

Form: tablets, modified release

ATC: G04CA53

Manufacturer: Adamed Pharma S.A.

The drug is used to treat men with benign prostatic hyperplasia who have not responded to monotherapy. It helps with bladder storage symptoms (frequent urination, urgency) and bladder emptying symptoms (urinary flow obstruction).

Form: tablets, modified release

ATC: G04CA53

Manufacturer: Avara Pharmaceuticals Technologies Inc. (manufacturing bulk)